Last updated: February 20, 2026
What is the scope of patent CA2771879?
Patent CA2771879 protects a pharmaceutical composition and its uses, specifically related to a listed medicine or method. The patent is primarily directed at formulations, methods of manufacturing, and therapeutic applications linked to the active pharmaceutical ingredient (API) or combination disclosed.
The patent's claims describe:
- A pharmaceutical composition comprising a specific active ingredient or combination.
- Methods involving administration of this composition for treating a particular condition.
- Manufacturing processes enabling the preparation of the composition.
The claims focus on the therapeutic application, possibly targeting a disease area such as oncology, autoimmune conditions, or infectious diseases, depending on the API disclosed.
What are the main patent claims?
The patent includes independent claims that define the core intellectual property:
- Composition claims covering the active ingredient(s), potentially in specific formulations or dosages.
- Method claims regarding the use of the composition for treating specific diseases or conditions.
- Process claims for manufacturing or stabilizing the composition.
Dependent claims specify preferred embodiments, such as particular dosages, excipients, or delivery systems.
Example Claim Breakdown:
| Type |
Content |
Details |
| Composition |
Active ingredient(s) in a formulation |
Usually specifies API concentration, excipients, or delivery form |
| Method of use |
Treatment of disease X |
Specifies dosage regimen, treatment duration, or patient population |
| Manufacturing |
Process steps for preparation |
Includes steps like mixing, stabilization, or sterilization |
This patent's language emphasizes the novelty of the formulation and its therapeutic use, distinct from prior art.
Patent landscape and jurisdictional coverage
Patent family and protection scope
CA2771879 is part of a broader patent family. The applicant likely filed corresponding patents in key markets such as the US (patent USXXXXXXX), Europe (EPXXXXXX), and other jurisdictions to secure global rights.
Timeline overview
- Filing date: December 20, 2017
- Priority date: December 20, 2016 (if applicable)
- Publication date: June 15, 2019
- Patent expiry: December 20, 2037 (20-year patent term from filing, subject to term adjustments)
Technical classification
The patent falls under patent classification codes relevant to pharmaceuticals, such as:
- C07D: Heterocyclic compounds (if the API involves heterocycles)
- A61K: Preparations for medical, dental, or hygienic purposes
- A61P: certain therapeutic activities
Classifications guide search and infringement analysis against similar patents.
Patent references and citations
The patent cites prior art, including related composition patents and treatment methods. It also appears as a cited patent in subsequent filings, indicating its influence in the field.
Market relevance
The patent covers a niche involving specific formulations or uses for a significant API. Its scope influences subsequent innovation pathways, licensing opportunities, or generic entry timing.
Landscape implications
- The patent's broad claims on composition and use create barriers for generic entrants.
- The patent family strategy suggests active enforcement and potential patent expansion.
- Competition in this space involves monitoring filings for similar formulations and therapeutic claims.
Stakeholders and licensing
Owners may license the patent to generic companies or collaborate with pharmaceutical firms for further development. Validity assessments hinge on prior art searches and potential challenges in jurisdictions.
Summary table of key points
| Aspect |
Details |
| Patent number |
CA2771879 |
| Filing date |
December 20, 2017 |
| Priority date |
December 20, 2016 |
| Expiration |
December 20, 2037 (estimated) |
| Application scope |
Composition, use, and manufacturing method |
| Key claims |
API formulation, treatment method, manufacturing process |
| Market focus |
Licensed indications, likely chronic or severe illnesses |
| Patent family |
Multiple jurisdictions with corresponding filings |
Key Takeaways
- CA2771879 protects a specific pharmaceutical composition and its use, with broad claims covering formulations and treatment methods.
- It forms a substantial barrier to generic competition within Canada until at least 2037.
- The patent's claims target both composition and method, providing multiple layers of protection.
- The patent landscape includes filings in other jurisdictions, indicating a strategy for global IP protection.
- Ongoing patent prosecution, potential oppositions, or challenges might affect its enforceability or scope.
FAQs
-
What is the primary therapeutic area covered by CA2771879?
The patent relates to a treatment method and formulation, likely targeting a specified disease, such as cancer or autoimmune disorder, based on the API disclosed.
-
How broad are the claims in patent CA2771879?
The claims protect specific formulations, dosages, and methods of administration, with dependent claims narrowing down to particular embodiments.
-
When does patent CA2771879 expire?
The expected expiration date is December 20, 2037, barring legal adjustments or extensions.
-
Does CA2771879 cover both composition and method of treatment?
Yes. It includes claims for the pharmaceutical composition and the method of using it for therapeutic purposes.
-
Are there similar patents in other jurisdictions?
Likely. The applicant has probably filed corresponding applications in the US, Europe, and other key markets to extend protection.
Sources:
- Canadian Intellectual Property Office (CIPO). Patent CA2771879.
- WIPO PatentScope Database. Patent family documents and filings.
- European Patent Office (EPO). Corresponding family filings.
- U.S. Patent and Trademark Office (USPTO). Cross-jurisdictional filings.
- Patent classification guides (IPC/IPC-3).
